Dunne's Weekly: Trump's Tariffs Still Pose Risks For New Zealand

The government’s relief that New Zealand seems to have escaped a bullet regarding President Trump’s tariffs may be short lived. New Zealand exporters will face a flat 10 percent tariff on goods sent to the United States, but that is at the lower end of the scale of tariffs Trump has imposed on other countries.

However, that may not be where New Zealand’s tariff travails end, if history and the experience of other countries is any guide.

In recent days, Trump has turned his attention to the international pharmaceutical industry, suggesting it was time to apply tariffs to pharmaceuticals because America “doesn’t make anything” in terms of drugs and medicines. He has particularly singled out Ireland, telling the country’s Prime Minister at the White House recently that "all of a sudden Ireland has our pharmaceutical companies, this beautiful island of five million people has got the entire US pharmaceutical industry in its grasp."

America is currently Ireland’s major export market, receiving around 28% of all its exports. Around two-thirds of Ireland’s exports to America are pharmaceutical products, manufactured by American companies operating under licence in Ireland. The Irish economy is therefore especially vulnerable to any new tariffs (potentially as high as 25%) Trump may impose on pharmaceuticals.

New Zealand has no pharmaceutical manufacturing industry to speak of so therefore is not vulnerable to tariffs in this way. But it does have the government’s drug procurement agency, PHARMAC, which America has long regarded as anti-competitive in relation to American products entering the New Zealand market.

PHARMAC was established in 1993 to arrange the purchase and supply of the medicines New Zealanders need. Its centralised approach and tough, single price negotiating stance has infuriated pharmaceutical companies the world over, arguably driving those that were operating in New Zealand at the time to move offshore. While PHARMAC has also been the recipient of constant local professional and political criticism for its hard-line approach, it has gained grudging recognition for the part it has played in keeping the country’s overall medicines bill under reasonable control.

However, America has been one of PHARMAC’s most constant and vehement critics, frequently citing its existence – let alone its operation – as a significant barrier to wider trade liberalisation between the two countries. On more than one occasion America has called for the paring back of PHARMAC’s role as the price of any form of freer trading arrangement between the two countries. To their credit, successive New Zealand governments have always resisted that pressure.

While PHARMAC does not appear to have been raised during the recent tariff discussions, it seems, given the recent comments about Ireland, only a matter of time before it is. With its preference for substituting cheaper generic drugs for brand-name drugs where feasible, PHARMAC could well be viewed by the Trump Administration as an impediment to the profitability of the American pharmaceutical industry in just the same way it views Ireland’s pharmaceutical manufacturing industry.

And if tariffs are to be imposed on Irish pharmaceutical exports to America, as seems highly likely, New Zealand should prepare for some sort of tariff imposition to blunt PHARMAC’s impact on the profitability of American pharmaceutical companies supplying to the local market. Because there is no New Zealand based pharmaceutical industry to speak of, any response from America will likely be retaliatory across a range of unrelated sectors but aimed at putting domestic political pressure on the government to bring PHARMAC to heel, the way America wishes.

In a word, it would be a case of good old-fashioned bullying, a trade practice America has frequently relied on over the years. In the late 1990s and early 2000s, New Zealand liberalised considerably its laws regarding parallel importing. Parallel importing is the practice of allowing the legal importation of genuine branded goods into a country without the consent or authorization of the brand owner or the official distributor in that market. Parallel imported goods are often cheaper on the retail market than the same goods supplied by the brand owner or official supplier. America lobbied the government of the day and individual politicians extremely hard against parallel importing, which it saw as detrimental to American brand owners, but to no avail.

Many of the arguments now being run by the Trump Administration that American manufacturers have been “ripped off” by cheap imports for years, which is why protective tariffs are now required, are very similar to those raised 25 years ago when parallel importing was an issue. In the current climate, there is no guarantee they will not be raised again insofar as New Zealand is concerned.

Against that backdrop, therefore, and given what seems to be a fast-moving international situation any sense of relief here that New Zealand has escaped the worst of the tariff impositions would be unwise. The recent tariff announcements seem unlikely to be the end of the matter. Trump likes to boast of the number of countries that have apparently approached the White House in the wake of the tariff announcements seeking new more- America friendly trade agreements instead of tariffs.

This makes it clear his wider agenda is to reshape the entire global trading structure away from the free trade emphasis that has dominated international trade discussions since the late 1980s. Trump not only wants to protect American manufacturers from competitive imports, but also to skew the entire global trading system in favour of America’s interests.

New Zealand was a leader in the global free trade movement of the late 1980s and early 1990s. As Trump tries to force the pendulum back the other way, we will not be able to avoid being caught up in the consequences of a struggle that has only just begun.

© Scoop Media